AU StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

RHYTHM BIOSCIENCES LTD

0.097

+0.0088.99%

Volume:182.13K

Turnover:17.42K

Market Cap:31.63M

PE:-6.82

High:0.098

Open:0.096

Low:0.092

Close:0.089

52wk High:0.210

52wk Low:0.047

Shares:326.07M

Float Shares:188.31M

Volume Ratio:0.09

T/O Rate:0.10%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-0.014

EPS(LYR):-0.014

ROE:-501.54%

ROA:-107.16%

PB:47.93

PE(LYR):-6.82

Loading ...

Overview Company News Filings

BRIEF-Rhythm Biosciences Seeks Trading Halt Pending Announcement Related To Capital Raise

Rhythm Biosciences Genetype Unit Signs Clinical Trial Support Deal with New York-Based Cancer Center; Shares Rise 4%

MT Newswires Live

BRIEF-Rhythm Biosciences Enters Service Agreement At Memorial Sloan Kettering Cancer Center

Rhythm Biosciences - Service Agreement to Support Clinical Trials at Memorial Sloan Kettering Cancer Center

THOMSON REUTERS

Rhythm Biosciences Launches Genetype Pilot With Australia's Top Pathology Provider

MT Newswires Live

Strategic Genetype Pilot with Leading Australian Pathology-RHY.AX

Change in substantial holding - Otto Buttula-RHY.AX

Change in substantial holding-RHY.AX

BRIEF-Rhythm Biosciences Receives Tranche Of A$1M In Non-Dilutive Funding From Endpoints Capital

ASX ALERT-FY2025 R&D Tax Incentive Loan Funding-RHY.AX

Rhythm Biosciences Secures Reinstatement of Accreditation for Cancer Risk Assessment Portfolio; Shares Down 3%

MT Newswires Live

ASX ALERT-NATA Accreditation Awarded for Genetype Laboratory-RHY.AX

Ceasing to be a substantial holder-RHY.AX

Rhythm Biosciences Chairman Resigns, Successor Named

MT Newswires Live

BRIEF-Rhythm Biosciences Says Gavin Fox-Smith To Assume Role Of Chairman

Board Composition Update Succession Plan-RHY.AX

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/RHY.AU/news?page=2"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"RHY.AU","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"RHY.AU\",,,,,undefined,":{"symbol":"RHY.AU","market":"AU","secType":"STK","nameCN":"RHYTHM BIOSCIENCES LTD","latestPrice":0.097,"timestamp":1766034720000,"preClose":0.089,"halted":0,"volume":182131,"delay":0,"nameEN":"RHYTHM BIOSCIENCES LTD","floatShares":188306561,"shares":326068419,"eps":-0.014222,"marketStatus":"Not Yet Opened","change":0.008,"latestTime":"12-18 16:12:00 AEDT","open":0.096,"high":0.098,"low":0.092,"amount":17422,"amplitude":0.067416,"askPrice":0.097,"askSize":7769,"bidPrice":0.092,"bidSize":300000,"shortable":3,"etf":0,"ttmEps":-0.014222,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":0,"beginTime":1766098800000},"marketStatusCode":0,"adr":0,"exchange":"ASX","adjPreClose":0.089,"openAndCloseTimeList":[[1766012400000,1766034000000]],"volumeRatio":0.086048,"lotSize":1,"tradeCurrency":"AUD"},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"RHY.AU\",,,,,undefined,":{"symbol":"RHY.AU","floatShares":188306561,"roa":"-107.16%","roe":"-501.54%","lyrEps":-0.014222,"volumeRatio":0.086048,"shares":326068419,"dividePrice":0,"high":0.098,"amplitude":0.067416,"preClose":0.089,"low":0.092,"week52Low":0.047,"pbRate":"47.93","psRate":"9.91","week52High":0.21,"institutionHeld":0,"latestPrice":0.097,"committee":0.949514,"eps":-0.014222,"divideRate":0,"volume":182131,"delay":0,"ttmEps":-0.014222,"open":0.096,"prevYearClose":0.087,"prevWeekClose":0.105,"prevMonthClose":0.086,"prevQuarterClose":0.083,"fiveDayClose":0.083,"twentyDayClose":0.087,"sixtyDayClose":0.091,"dividendGrowthYears":0,"fiveYearAvgDividendRate":0},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/RHY.AU\",params:#limit:5,,,undefined,":[{"market":"AU","date":"2020-07-27","symbol":"RHY.AU","type":"split","dateTimestamp":1595772000000,"forFactor":875,"toFactor":1000,"ratio":0.875}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"RHY.AU\",market:\"AU\",,,undefined,":[],"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"RHY.AU\",pageSize:20,pageCount:2,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2559938935","title":"BRIEF-Rhythm Biosciences Seeks Trading Halt Pending Announcement Related To Capital Raise","url":"https://stock-news.laohu8.com/highlight/detail?id=2559938935","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2559938935?lang=en_us&edition=fundamental","pubTime":"2025-08-14 09:14","pubTimestamp":1755134066,"startTime":"0","endTime":"0","summary":"BRIEF-Rhythm Biosciences Seeks Trading Halt Pending Announcement Related To Capital RaiseAug 14 (Reuters) - Rhythm Biosciences Ltd RHY.AX:SEEKS TRADING HALT PENDING ANNOUNCEMENT RELATED TO CAPITAL RAISEFurther company coverage: RHY.AX ((Reuters.Briefs@thomsonreuters.com;))","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250814:nFWN3U51M7:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7124","RHY.AU"],"gpt_icon":0},{"id":"2553741276","title":"Rhythm Biosciences Genetype Unit Signs Clinical Trial Support Deal with New York-Based Cancer Center; Shares Rise 4%","url":"https://stock-news.laohu8.com/highlight/detail?id=2553741276","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2553741276?lang=en_us&edition=fundamental","pubTime":"2025-07-24 14:00","pubTimestamp":1753336852,"startTime":"0","endTime":"0","summary":"Rhythm Biosciences  said its Genetype unit has entered into a service agreement to support clinical trials at Memorial Sloan Kettering Cancer Center , a cancer treatment and research institution based in New York City, according to a Thursday Australian bourse filing.This new service agreement supports at least two subsequent clinical trials that build on the previous work with the MSK team carrying out these studies.The company said the studies are not yet underway, but that it will process at least an estimated 300 participants from both studies.The company's shares rose nearly 4% in recent Thursday trade.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7124","RHY.AU"],"gpt_icon":0},{"id":"2553377224","title":"BRIEF-Rhythm Biosciences Enters Service Agreement At Memorial Sloan Kettering Cancer Center","url":"https://stock-news.laohu8.com/highlight/detail?id=2553377224","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2553377224?lang=en_us&edition=fundamental","pubTime":"2025-07-24 09:39","pubTimestamp":1753321179,"startTime":"0","endTime":"0","summary":"BRIEF-Rhythm Biosciences Enters Service Agreement At Memorial Sloan Kettering Cancer CenterJuly 24 (Reuters) - Rhythm Biosciences Ltd RHY.AX:SERVICE AGREEMENT TO SUPPORT CLINICAL TRIALS AT MEMORIAL SLOAN KETTERING CANCER CENTERFurther company coverage: RHY.AX ((Reuters.Briefs@thomsonreuters.com;))","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250724:nFWN3TK1J9:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7124","RHY.AU"],"gpt_icon":0},{"id":"2553257762","title":"Rhythm Biosciences - Service Agreement to Support Clinical Trials at Memorial Sloan Kettering Cancer Center","url":"https://stock-news.laohu8.com/highlight/detail?id=2553257762","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2553257762?lang=en_us&edition=fundamental","pubTime":"2025-07-24 07:07","pubTimestamp":1753312068,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250723:nFWN3TK1J9:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["RHY.AU","BK7124"],"gpt_icon":0},{"id":"2552109743","title":"Rhythm Biosciences Launches Genetype Pilot With Australia's Top Pathology Provider","url":"https://stock-news.laohu8.com/highlight/detail?id=2552109743","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2552109743?lang=en_us&edition=fundamental","pubTime":"2025-07-17 15:41","pubTimestamp":1752738087,"startTime":"0","endTime":"0","summary":"Rhythm Biosciences  said that its Genetype subsidiary business has secured its first strategic pilot partnership with a leading pathology service provider in Australia, advancing the company's predictive cancer diagnostics technology, according to a Thursday Australian bourse filing.The partnership brings dedicated resources from both sides to drive innovation in cancer, coronary, and diabetes risk assessment through personalized medicine, expanding patient access to genotyping tests, and setting the stage for wider commercial deployment and increased revenue potential, the filing added.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["XJO.AU","XAO.AU","XKO.AU","BK7124","RHY.AU"],"gpt_icon":0},{"id":"2552117512","title":"Strategic Genetype Pilot with Leading Australian Pathology-RHY.AX","url":"https://stock-news.laohu8.com/highlight/detail?id=2552117512","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2552117512?lang=en_us&edition=fundamental","pubTime":"2025-07-17 06:47","pubTimestamp":1752706057,"startTime":"0","endTime":"0","summary":"https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250716:nASX79VbCP","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250716:nASX1TPjmh:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RHY.AU","BK7124"],"gpt_icon":0},{"id":"2550358683","title":"Change in substantial holding - Otto Buttula-RHY.AX","url":"https://stock-news.laohu8.com/highlight/detail?id=2550358683","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2550358683?lang=en_us&edition=fundamental","pubTime":"2025-07-09 14:43","pubTimestamp":1752043409,"startTime":"0","endTime":"0","summary":"https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250709:nASX9WyV4S","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250709:nASX3mSGqh:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RHY.AU","BK7124"],"gpt_icon":0},{"id":"2548873563","title":"Change in substantial holding-RHY.AX","url":"https://stock-news.laohu8.com/highlight/detail?id=2548873563","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2548873563?lang=en_us&edition=fundamental","pubTime":"2025-07-03 15:12","pubTimestamp":1751526777,"startTime":"0","endTime":"0","summary":"https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250703:nASX2qxMkx","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250703:nASX17rhSx:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7124","RHY.AU"],"gpt_icon":0},{"id":"2547106399","title":"BRIEF-Rhythm Biosciences Receives Tranche Of A$1M In Non-Dilutive Funding From Endpoints Capital","url":"https://stock-news.laohu8.com/highlight/detail?id=2547106399","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2547106399?lang=en_us&edition=fundamental","pubTime":"2025-06-30 16:19","pubTimestamp":1751271558,"startTime":"0","endTime":"0","summary":"BRIEF-Rhythm Biosciences Receives Tranche Of A$1M In Non-Dilutive Funding From Endpoints CapitalJune 30 (Reuters) - Rhythm Biosciences Ltd RHY.AX:RECEIVED TRANCHE OF A$1M IN NON-DILUTIVE FUNDING FROM ENDPOINTS CAPITALFurther company coverage: RHY.AX ((Reuters.Briefs@thomsonreuters.com))","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250630:nFWN3SX08U:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RHY.AU","BK7124"],"gpt_icon":0},{"id":"2547050689","title":"ASX ALERT-FY2025 R&D Tax Incentive Loan Funding-RHY.AX","url":"https://stock-news.laohu8.com/highlight/detail?id=2547050689","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2547050689?lang=en_us&edition=fundamental","pubTime":"2025-06-30 15:29","pubTimestamp":1751268572,"startTime":"0","endTime":"0","summary":"https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250630:nASX1wXy9N","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250630:nASXt1lQy:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7124","RHY.AU"],"gpt_icon":0},{"id":"2545747617","title":"Rhythm Biosciences Secures Reinstatement of Accreditation for Cancer Risk Assessment Portfolio; Shares Down 3%","url":"https://stock-news.laohu8.com/highlight/detail?id=2545747617","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2545747617?lang=en_us&edition=fundamental","pubTime":"2025-06-24 11:58","pubTimestamp":1750737497,"startTime":"0","endTime":"0","summary":"Rhythm Biosciences  secures a reinstatement of its National Association of Testing Authorities accreditation for the geneType cancer risk assessment assay portfolio, according to a Tuesday filing with the Australian bourse.This follows the temporary suspension of the accreditation after the company acquired the geneType assets from Genetic Technologies , the filing said.The reinstatement marks the conclusion of the integration of the geneType laboratory under the company's ownership, per the filing.Shares were down 3% in afternoon trade on Tuesday.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7124","GTG.AU","BK7048","BK7508","RHY.AU"],"gpt_icon":0},{"id":"2545498425","title":"ASX ALERT-NATA Accreditation Awarded for Genetype Laboratory-RHY.AX","url":"https://stock-news.laohu8.com/highlight/detail?id=2545498425","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2545498425?lang=en_us&edition=fundamental","pubTime":"2025-06-24 07:17","pubTimestamp":1750720629,"startTime":"0","endTime":"0","summary":"https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250623:nASXgVLqQ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250623:nASX6B8Kch:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RHY.AU","BK7124"],"gpt_icon":0},{"id":"2545467159","title":"Ceasing to be a substantial holder-RHY.AX","url":"https://stock-news.laohu8.com/highlight/detail?id=2545467159","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2545467159?lang=en_us&edition=fundamental","pubTime":"2025-06-23 14:35","pubTimestamp":1750660550,"startTime":"0","endTime":"0","summary":"https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250623:nASX1yd8nn","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250623:nASX5FVLsc:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7124","RHY.AU"],"gpt_icon":0},{"id":"2545688014","title":"Rhythm Biosciences Chairman Resigns, Successor Named","url":"https://stock-news.laohu8.com/highlight/detail?id=2545688014","media":"MT Newswires Live","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2545688014?lang=en_us&edition=fundamental","pubTime":"2025-06-23 10:16","pubTimestamp":1750644977,"startTime":"0","endTime":"0","summary":"Rhythm Biosciences  said that Non-Executive Chairman Otto Buttula plans to step down as both chair and director at the company's current year annual general meeting, according to a Monday Australian bourse filing.Gavin Fox-Smith will succeed Buttula as chairman following his retirement, the filing said.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["XAO.AU","BK7124","XJO.AU","RHY.AU","XKO.AU"],"gpt_icon":0},{"id":"2545459031","title":"BRIEF-Rhythm Biosciences Says Gavin Fox-Smith To Assume Role Of Chairman","url":"https://stock-news.laohu8.com/highlight/detail?id=2545459031","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2545459031?lang=en_us&edition=fundamental","pubTime":"2025-06-23 07:54","pubTimestamp":1750636486,"startTime":"0","endTime":"0","summary":"BRIEF-Rhythm Biosciences Says Gavin Fox-Smith To Assume Role Of ChairmanJune 23 (Reuters) - Rhythm Biosciences Ltd RHY.AX:GAVIN FOX-SMITH TO ASSUME ROLE OF CHAIRMAN AT 2025 AGMFurther company coverage: RHY.AX ((Reuters.Briefs@thomsonreuters.com;))","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250622:nFWN3SO03F:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7124","RHY.AU"],"gpt_icon":0},{"id":"2545459600","title":"Board Composition Update Succession Plan-RHY.AX","url":"https://stock-news.laohu8.com/highlight/detail?id=2545459600","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2545459600?lang=en_us&edition=fundamental","pubTime":"2025-06-23 07:10","pubTimestamp":1750633841,"startTime":"0","endTime":"0","summary":"https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250622:nASX9d8SSY","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250622:nASX9Nv0XF:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7124","RHY.AU"],"gpt_icon":0}],"pageSize":20,"totalPage":2,"pageCount":2,"totalSize":36,"code":"91000000","status":"200"}]}}